Literature DB >> 28398925

Urgent Chemotherapy for Life-Threatening Complications Related to Solid Neoplasms.

Yoann Zerbib1, Antoine Rabbat, Muriel Fartoukh, Naïke Bigé, Claire Andréjak, Julien Mayaux, Nicolas De Prost, Benoît Misset, Virginie Lemiale, Fabrice Bruneel, Julien Maizel, Sylvie Ricome, Frédéric Jacobs, Caroline Bornstain, Hervé Dupont, François Baudin, Elie Azoulay, Frédéric Pène.   

Abstract

OBJECTIVES: Solid neoplasms can be directly responsible for organ failures at the time of diagnosis or relapse. The management of such specific complications relies on urgent chemotherapy and eventual instrumental or surgical procedures, combined with advanced life support. We conducted a multicenter study to address the prognosis of this condition.
DESIGN: A multicenter retrospective (2001-2015) chart review.
SETTING: Medical and respiratory ICUs. PATIENTS: Adult patients who received urgent chemotherapy in the ICU for organ failure related to solid neoplasms were included. The modalities of chemotherapy, requirements of adjuvant instrumental or surgical procedures, and organ supports were collected. Endpoints were short- and long-term survival rates.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: One hundred thirty-six patients were included. Lung cancer was the most common malignancy distributed into small cell lung cancer (n = 57) and non-small cell lung cancer (n = 33). The main reason for ICU admission was acute respiratory failure in 111 patients (81.6%), of whom 89 required invasive mechanical ventilation. Compression and tissue infiltration by tumor cells were the leading mechanisms resulting in organ involvement in 78 (57.4%) and 47 (34.6%) patients. The overall in-ICU, in-hospital, 6-month, and 1-year mortality rates were 37%, 58%, 74%, and 88%, respectively. Small cell lung cancer was identified as an independent predictor of hospital survival. However, this gain in survival was not sustained since the 1-year survival rates of small cell lung cancer, non-small cell lung cancer, and non-lung cancer patients all dropped below 20%.
CONCLUSIONS: Urgent chemotherapy along with aggressive management of organ failures in the ICU can be lifesaving in very selected cancer patients, most especially with small cell lung cancer, although the long-term survival is hardly sustainable.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28398925     DOI: 10.1097/CCM.0000000000002331

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

1.  Management of superior vena cava syndrome in critically ill cancer patients.

Authors:  Sarah Morin; Adeline Grateau; Danielle Reuter; Eric de Kerviler; Constance de Margerie-Mellon; Cédric de Bazelaire; Lara Zafrani; Benoit Schlemmer; Elie Azoulay; Emmanuel Canet
Journal:  Support Care Cancer       Date:  2017-08-24       Impact factor: 3.603

2.  Characteristics and outcomes of patients with solid tumors receiving chemotherapy in the intensive care unit.

Authors:  David J Shaz; Stephen M Pastores; Debra A Goldman; Natalie Kostelecky; Richard F Tizon; Kay See Tan; Neil A Halpern
Journal:  Support Care Cancer       Date:  2019-12-14       Impact factor: 3.603

3.  Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors.

Authors:  Richard Benjamin Young; Hemali Panchal; Weijie Ma; Shuai Chen; Aaron Steele; Andrea Iannucci; Tianhong Li
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

4.  Characteristics and outcome of patients with newly diagnosed advanced or metastatic lung cancer admitted to intensive care units (ICUs).

Authors:  C Barth; M Soares; A C Toffart; J F Timsit; G Burghi; C Irrazabal; N Pattison; E Tobar; B F Almeida; U V Silva; L C Azevedo; A Rabbat; C Lamer; A Parrot; V C Souza-Dantas; F Wallet; F Blot; G Bourdin; C Piras; J Delemazure; M Durand; J Salluh; E Azoulay; Virginie Lemiale
Journal:  Ann Intensive Care       Date:  2018-08-04       Impact factor: 6.925

5.  Etiologies of delayed diagnosis and six-month outcome of patients with newly diagnosed advanced lung cancer with respiratory failure at initial presentation.

Authors:  How-Yang Tseng; Yi-Cheng Shen; Yen-Sung Lin; Chih-Yen Tu; Hung-Jen Chen
Journal:  Thorac Cancer       Date:  2020-08-06       Impact factor: 3.500

6.  One-year survival of patients with high-grade glioma discharged alive from the intensive care unit.

Authors:  Maxens Decavèle; Nicolas Gatulle; Nicolas Weiss; Isabelle Rivals; Ahmed Idbaih; Sophie Demeret; Julien Mayaux; Martin Dres; Elise Morawiec; Khe Hoang-Xuan; Thomas Similowski; Alexandre Demoule
Journal:  J Neurol       Date:  2020-08-29       Impact factor: 4.849

7.  Patterns of ICU admissions and outcomes in patients with solid malignancies over the revolution of cancer treatment.

Authors:  Clara Vigneron; Julien Charpentier; Sandrine Valade; Jérôme Alexandre; Samy Chelabi; Lola-Jade Palmieri; Nathalie Franck; Valérie Laurence; Jean-Paul Mira; Matthieu Jamme; Frédéric Pène
Journal:  Ann Intensive Care       Date:  2021-12-24       Impact factor: 6.925

Review 8.  Critically ill patients with cancer: A clinical perspective.

Authors:  Frank Daniel Martos-Benítez; Caridad de Dios Soler-Morejón; Karla Ximena Lara-Ponce; Versis Orama-Requejo; Dailé Burgos-Aragüez; Hilev Larrondo-Muguercia; Rahim W Lespoir
Journal:  World J Clin Oncol       Date:  2020-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.